Heterogeneity in Definitions of Efficacy and Safety Endpoints for Clinical Trials of Crohn's Disease: A Systematic Review.

Date publication

septembre 2018

Journal

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent

Tous les auteurs :
Ma C, Hussein IM, Al-Abbar YJ, Panaccione R, Fedorak RN, Parker CE, Nguyen TM, Khanna R, Siegel CA, Peyrin-Biroulet L, Pai RK, Vande Casteele N, D'Haens GR, Sandborn WJ, Feagan BG, Jairath V

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/29596987

Résumé

Endpoints in randomized controlled trials (RCTs) of Crohn's disease (CD) are changing. We performed a systematic review of efficacy and safety outcomes reported in placebo-controlled RCTs of patients with CD.

Mots clés

Effects, IBD, Inflammatory Bowel Disease, RCT, Treatment

Référence

Clin. Gastroenterol. Hepatol.. 2018 Sep;16(9):1407-1419.e22